Injection site and pharmacokinetics after intravitreal injection of immunoglobulin G

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 35-41

  Miura, Yoko ^a   Uematsu, Masafumi ^a   Teshima, Mugen ^a   Suzuma, Kiyoshi ^a   Kumagami, Takeshi ^a   Sasaki, Hitoshi ^b   Kitaoka, Takashi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CILIARY DISK; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXPERIMENTAL RABBIT; INJECTION SITE; MALE; NONHUMAN; RETINA; VITREOUS BODY;

ANIMALS; CHOROID; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTRAVITREAL INJECTIONS; MALE; OSMOLAR CONCENTRATION; PHARMACOKINETICS; RABBITS; RETINA; TIME FACTORS; VITREOUS BODY;

EID: 79952000232     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0112     Document Type: Article

References (20)

1. Kook, D., Wolf, A., Kreutzer, T., et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28:1053-1060, 2008.
2. Arevalo, J.F., Sanchez, J.G., Fromow-Guerra, J., et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study group (PACORES) at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 247:735-743, 2009.
3. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Opthalmology 113:363-372, 2006.
4. Bashshur, Z.F., Haddad, Z.A., Schakal, A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145:249-256, 2008.
5. Arevalo, J.F., Fromow-Guerra, J., Sanchez, J.G., et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 28:1387-1394, 2008.
6. Pai, S.A., Shetty, R., Vijayan, P.B., et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macula edema in retinal vein occlusion. Am. J. Ophthalmol. 143:601-606, 2007.
7. Kriechbaum, K., Michels, S., Prager, F., et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol. 92:518-522, 2008.
8. Avery, R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354, 2006. (Pubitemid 44318195)
9. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859, 2007. (Pubitemid 46635858)
10. Shahar, J., Avery, R.L., Heilweil, G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269, 2006. (Pubitemid 44318177)
11. Heiduschka, P., Fietz, H., Hofmeister, S., et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 48:2814-2823, 2007.
12. Ameri, H., Chader, G.J., Kim, J.-G., et al. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest. Ophthalmol. Vis. Sci. 48:5708-5715, 2007.
13. Peters, S., Heiduschka, P., Julien, S., et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am. J. Ophthalmol. 143:995-1002, 2007.
14. Peters, S., Heiduschka, P., Julien, S., et al. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br. J. Ophthalmol. 92:541-544, 2008.
15. Dib, E., Maia, M., Longo-Maugeri, I.M., et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest. Ophthalmol. Vis. Sci. 49:1097-1100, 2008.
16. Nomoto, H., Shiraga, F., Kuno, N., et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 50:4807-4813, 2009.
17. Julien, S., Heiduschka, P., Hofmeister, S., and Schraermeyer, U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. Br. J. Ophthalmol. 92:1424-1428, 2008.
18. Uematsu, M., Koga, M., Yamada, K., et al. Usefulness of a fixation ring guide for intravitreous injection needles. Asian J. Ophthalmol. 8:156, 2006.
19. Jager, R.D., Aiello, L.P., Patel, S.C., et al. Risks of intravitreous injection: a comprehensive review. Retina 24:676-698, 2004. (Pubitemid 39391758)
20. Aiello, L.P., Brucker, A.J., Chang, S., et al. Evolving guidelines for intravitreous injections. Retina 24:S3-S19, 2004. (Pubitemid 39391785)